SCHEMBL2495288

SCHEMBL2495288

O=C(c1ccccn1)c1cn(-c2cccc(-c3ccccc3)c2)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.44
HDAC1 Q13547 1/20 0.42
COMT P21964 3/20 0.42
GRM5 P41594 3/20 0.42
LMNA P02545 2/20 0.41
NAPRT Q6XQN6 1/20 0.41
P4HTM Q9NXG6 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ESRRA P11474 1/20 0.40
MLLT3 P42568 1/20 0.40
MLLT1 Q03111 1/20 0.40
KDM4E B2RXH2 1/20 0.39
USP2 O75604 2/20 0.39
CYP1A2 P05177 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C19 P33261 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
CES2 O00748 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2502844 0.86 HSD17B14 (0.38) KMT2AGRM5MLLT3MLLT1
SCHEMBL2498936 0.86 SCN9A (0.45) KMT2AGRM5MLLT3MLLT1ALDH1A1
SCHEMBL2502818 0.85 COMT (0.45) KMT2ACOMTGRM5L3MBTL1ESRRA
SCHEMBL2502794 0.85 CTSA (0.37) KMT2AGRM5MLLT3MLLT1KDM4E
SCHEMBL2497581 0.84 HSD17B14 (0.39) KMT2AGRM5LMNAMLLT3MLLT1
SCHEMBL1879655 0.84 KDM4E (0.50) COMTMLLT3MLLT1KDM4E
SCHEMBL2495406 0.83 GRM5 (0.48) GRM5LMNAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL2497621 0.83 GABRA1 (0.43) GRM5
SCHEMBL2497732 0.82 CTSA (0.39) KMT2AGRM5MLLT3MLLT1USP2
SCHEMBL2497361 0.81 COMT (0.46) COMTESRRAMLLT3MLLT1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030339-B2 Imidazole derivatives for the treatment of anxiety and related diseases NEUROSEARCH A/S (DK) 2011-10-04 US claimed
US-20090233929-A1 Imidazole Derivatives for the Treatment of Anxiety and Related Diseases NEUROSEARCH A/S (DK) 2009-09-17 US claimed
EP-1937649-A1 IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES NEUROSEARCH A/S (DK) 2008-07-02 EP claimed
WO-2007042546-A1 IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES NEUROSEARCH A/S (DK) 2007-04-19 WO claimed
US-8030339-B2 Imidazole derivatives for the treatment of anxiety and related diseases NEUROSEARCH A/S (DK) 2011-10-04 US disclosed
US-20090233929-A1 Imidazole Derivatives for the Treatment of Anxiety and Related Diseases NEUROSEARCH A/S (DK) 2009-09-17 US disclosed
EP-1937649-A1 IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES NEUROSEARCH A/S (DK) 2008-07-02 EP disclosed
WO-2007042546-A1 IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES NEUROSEARCH A/S (DK) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233929-A1 Imidazole Derivatives for the Treatment of Anxiety and Related Diseases GABBR1, GABRB2, GABRB3 KMT2A 1249/4885HDAC1 492/4885COMT 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.